Genetic Signatures appoints interim managing director

Genetic Signatures (ASX:GSS) has appointed Non-Executive Director Anne Lockwood as its interim Managing Director to fortify its leadership during a strategic transition period.

Bringing over 30 years of expertise in finance and risk management—including high-level roles at EY and as CFO of Integral Diagnostics—Lockwood is tasked with overseeing financial discipline and corporate governance for an initial six-month term.

She will work alongside the newly appointed CEO, Maria Halasz, a move the Board indicates will streamline costs and ensure operational continuity following the recent departures of the former CEO and CFO.

Consequently, the search for a permanent CFO has been deferred while Lockwood handles the dual priorities of financial oversight and strategic execution.

At the time of reporting, Genetic Signatures' share price was $0.15.